Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study
- DOI
- 10.1007/s13555-026-01973-x
- Published
- 2026-11-08
- Container
- Dermatology and Therapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-026-01973-x,
title = {Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study},
author = {Eugenia Veronica Di Brizzi and Panetti Carlo and Maria Maddalena Nicoletti and Paolino Franzese and Stefano Caccavale and Giuseppe Argenziano and Anna Balato},
year = {2026},
journal = {Dermatology and Therapy},
doi = {10.1007/s13555-026-01973-x},
url = {https://doi.org/10.1007/s13555-026-01973-x}
}RIS
TY - JOUR TI - Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study AU - Eugenia Veronica Di Brizzi AU - Panetti Carlo AU - Maria Maddalena Nicoletti AU - Paolino Franzese AU - Stefano Caccavale AU - Giuseppe Argenziano AU - Anna Balato PY - 2026 JO - Dermatology and Therapy DO - 10.1007/s13555-026-01973-x UR - https://doi.org/10.1007/s13555-026-01973-x ER -
APA
Brizzi, E. V. D., Carlo, P., Nicoletti, M. M., Franzese, P., Caccavale, S., Argenziano, G., & Balato, A. (2026). Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01973-x
Source records
- crossref · retrieved 2026-11-09T03:05:12.534Z